<DOC>
	<DOCNO>NCT01739933</DOCNO>
	<brief_summary>Ventilated ICU patient frequently sepsis majority delirium , form brain dysfunction independent predictor increase risk dying , length stay , cost , prolong cognitive impairment survivor . Universally prescribed sedative medications—the GABA-ergic benzodiazepines—worsen brain organ dysfunction . The available alternative sedation regimen , short act GABA-ergic propofol , alpha2 agonist , dexmedetomidine , show superior benzodiazepine , yet different regard effect innate immunity , bacterial clearance , apoptosis , cognition delirium . The MENDS II study compare propofol dexmedetomidine , determine best sedative medication reduce delirium improve survival long-term brain function vulnerable patients— ventilate septic patient .</brief_summary>
	<brief_title>The MENDSII Study , Maximizing Efficacy Sedation Reducing Neurological Dysfunction Mortality Septic Patients With Acute Respiratory Failure</brief_title>
	<detailed_description>The need mechanical ventilation ( MV ) secondary sepsis lead cause admission intensive care unit , often necessitating sedation patient safety comfort . Recently , learn sedative medication contribute iatrogenic injury , prolong ventilator time ICU length stay exacerbate acute brain dysfunction . This acute brain dysfunction , manifest delirium coma , occur 50 % -70 % MV septic patient significant contributor death also functional cognitive decline , persist year recovery lung organ function , levy significant cost patient society . Despite advance management acute respiratory failure sepsis , clinical trial examine effect supportive therapy , like sedation , may short- long-term outcome vulnerable population . The gamma-aminobutyric acid ( GABA ) -ergic benzodiazepine , particular , show increase brain dysfunction , promote infection , prolong MV . Therefore , short-acting GABA-ergic sedative propofol alpha2 agonist dexmedetomidine become widely use sedate septic MV patient . There randomized trial , however , guide clinician select sedative , none explore mechanism underlie difference outcomes , though data indicate GABA-ergic alpha2 agonist agent different effect innate immunity , apoptosis , arousability , respiratory drive . In early animal human study , dexmedetomidine anti-inflammatory effect GABA-ergic agent ; dexmedetomidine improve bacterial clearance , whereas propofol impair . In addition , sedation dexmedetomidine instead benzodiazepine reduces delirium 20 % -30 % improve arousability , cognition , attentiveness ventilate patient . Alpha2 agonists induce unconsciousness brainstem—more akin natural sleep—which may improve autonomic function immunity . All factor converge suggest sedation alpha2 agonist rather GABAergic agent may improve outcome , include brain function , MV , survival , septic MV patient . We therefore propose MENDS II ( Maximizing Efficacy Sedation Reducing Neurological Dysfunction Mortality Septic Patients Acute Respiratory Failure ) study , test hypothesis sedation MV severely septic patient alpha2 agonist ( dexmedetomidine ) rather GABAergic agent ( propofol ) ( Aim 1A ) increase day alive without delirium coma , ( Aim 1B ) increase ventilator-free day , ( Aim 2A ) improve 90-day survival , ( Aim 2B ) decrease long-term cognitive impairment , ( Aim 3 ) reduce pro-inflammatory cytokine cascade follow sepsis . We randomize 530 ventilate , severely septic patient require goal-directed sedation dexmedetomidine propofol , give study 90 % power detect difference 1.5 delirium/coma-free day absolute difference mortality 10 % two group .</detailed_description>
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Delirium</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>Consecutive patient eligible inclusion MENDS II study : [ 1 ] adult patient ( ≥18 year old ) [ 2 ] medical and/or surgical ICU [ 3 ] MV require sedation [ 4 ] suspect known infection Patients exclude ( i.e. , consent ) follow reason : 1 . Rapidly resolve organ failure , indicate plan immediate discontinuation MV , time screen study enrollment 2 . Pregnant breastfeed 3 . Severe dementia neurodegenerative disease , define either impairment prevents patient live independently baseline IQCODE &gt; 4.5 , measure use patient 's qualified surrogate . This exclusion also pertain mental illness require longterm institutionalization , acquire congenital mental retardation , severe neuromuscular disorder , Parkinson 's disease , Huntington 's disease . It also exclude patient coma severe deficit due structural brain disease stroke , intracranial hemorrhage , cranial trauma , malignancy , anoxic brain injury , cerebral edema . 4 . History 2nd 3rd degree heart block , bradycardia &lt; 50 beats/minute , pacemaker bradyarrythmias uncompensated shock.If patient pacemaker bradyarrythmias , patient meet exclusion criterion may enrol . 5 . Benzodiazepine dependency history alcohol dependency base medical team 's decision institute specific treatment plan involve benzodiazepine ( either continuous infusion intermittent intravenous bolus ) dependency . 6 . Active seizure ICU admission treat intravenous benzodiazepine . 7 . Expected death within 24 hour enrollment lack commitment aggressive treatment family/medical team ( e.g. , likely withdraw life support measure within 24 hr screen ) 8 . Inability understand English deafness vision loss preclude delirium evaluation . The inability understand English ( example Spanishonly Mandarinonly speak patient ) result exclusion center research staff proficient and/or translation service actively available particular language ; patient follow longterm followup phase trial since test material primarily available English . Patients laryngectomies hear deficit eligible enrollment medical condition permit communicate research staff . 9 . Inability obtain informed consent authorize representative within 48 hour meet inclusion criterion , i.e. , develop sepsis qualify organ dysfunction criterion follow reason : 1 . Attending physician refusal . 2 . Patient and/or surrogate refusal . 3 . Patient unable consent surrogate available . 4 . 48hour period eligibility exceed patient screen . 10 . Prisoners . 11 . Medical team follow patient unwilling use sedation regimen . 12 . Documented allergy propofol dexmedetomidine . 13 . Current enrollment study allow coenrollment use delirium primary outcome . 14 . Patients muscle relaxant infusion time screen plan maintain paralysis &gt; 48 hour . 15 . Greater 96 hour mechanical ventilation prior meet inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Delirium</keyword>
	<keyword>Delirium/coma-free day</keyword>
	<keyword>Long term cognitive impairment</keyword>
	<keyword>Sedation</keyword>
	<keyword>Intensive care</keyword>
	<keyword>Mechanical Ventilation</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Propofol</keyword>
	<keyword>Coma-free day</keyword>
	<keyword>Sepsis</keyword>
	<keyword>Organ dysfunction</keyword>
	<keyword>Acute Respiratory Distress</keyword>
	<keyword>Markers inflammation</keyword>
</DOC>